EGF+61 A&gt;G polymorphism is not associated with lung cancer risk in the Brazilian population

Laus, Ana Carolina; Paula, Flávia Escremim de; Lima, Marcos Alves de; Carlos, Carolina Dias; Gomes, Izabela Natália Faria; Marchi, Pedro De; Valente, Jenna Kadja Neves; Pioltini, Ana Beatriz Maringolo; Miziara, Juliana Muniz; Silva, Carlos Maciel da; Viana, Luciano de Souza; Scapulatempo‐Neto, Cristovam; Reis, Rui Manuel

doi:10.1007/s11033-019-04702-0

Cited by 5 publications

(6 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They revealed that they did not see any noticeable difference in AA, GG, and AG genotypes between lung cancer patients and control groups. They also did not report evidence of a direct relationship between lung cancer and the EGF + 61 A > G polymorphism (Laus et al, 2019). The binding of EGF to its receptor, EGFR, during activity indicates that EGFR has a substantial role as a regulator of this process.…”

Section: Discussionmentioning

confidence: 99%

The association of epidermal growth factor variant with oral squamous cell carcinoma

Ertugrul,

Mohammed,

Kasarci

et al. 2023

Environ and Mol Mutagen

View full text Add to dashboard Cite

In this study, our aim was to investigate the epidermal growth factor (EGF) and epidermal growth factor receptor (EGFR) gene polymorphisms in oral squamous cell carcinoma (OSCC) patients and non‐OSCC healthy controls. This case‐control study comprised 89 OSCC and 107 healthy controls by using polymerase chain reaction (PCR) and restriction‐fragment‐length‐polymorphism methods, the genotypes for EGF +61 A>G (rs4444903) and EGFR R497K (rs2227983) were analyzed. According to the EGF +61 A>G genotype distribution, individuals with the GG genotype were more prevalent in the OSCC group when compared to the healthy controls. But the AA genotype frequency was significantly higher in the healthy control group. The frequency of G allele carriers was 2.3 times higher than A allele carriers in OSCC patients (p<0.001). For the EGFR R497K genotype, there was no significant difference between the OSCC and healthy control groups. Regarding the study results, the G allele of EGF +61 A>G polymorphism was associated with OSCC. Larger populations and functional investigations should be used to explore the nature of the interaction between EGF and OSCC.This article is protected by copyright. All rights reserved.

show abstract

Section: Discussionmentioning

confidence: 99%

The association of epidermal growth factor variant with oral squamous cell carcinoma

Ertugrul,

Mohammed,

Kasarci

et al. 2023

Environ and Mol Mutagen

View full text Add to dashboard Cite

show abstract

“…In other words, rs4444903 polymorphism in the EGF gene promoter can affect EGF production [13]. EGF rs4444903 polymorphism has been investigated in many diseases, including colorectal cancer [38], gastrointestinal cancer [39], lung cancer [40] and glioma [41]. HCC is also among these cancers that cannot be ignored.…”

Section: Discussionmentioning

confidence: 99%

EGF rs4444903 polymorphism is associated with risk of HCV-related cirrhosis and HBV/HCV-related hepatocellular carcinoma

2021

View full text Add to dashboard Cite

Objective The epidermal growth factor (EGF) rs4444903 polymorphism is associated with aberrant expression of EGF, which was a characteristic of cirrhotic liver diseases, induces highly malignant hepatocellular carcinoma (HCC). Numerous studies have uncovered the association of this polymorphism with the risk of liver disease, but with inconsistent findings. Materials and methods Therefore, this meta-analysis was performed to evaluate whether EGF rs4444903 polymorphism conferred susceptibility to liver disease. Totally 18 eligible articles were identified by searching PubMed, Google, CNKI and EMBASE up to December 1, 2020. Results Our results indicated that there was no significant difference in the minor G allele frequency of rs4444903 polymorphism between HBV/HCV carriers and healthy controls. In other words, EGF rs4444903 polymorphism was not associated with the risk of HBV/HCV. Interestingly, this polymorphism increased the risk of liver cirrhosis in the controls with HCV infection. Additionally, EGF rs4444903 polymorphism is associated with the increased risk of HCC under the five models. Subgroup analysis by ethnicity shows that rs4444903 polymorphism intensifies the risk of HCC among Asians and Caucasians. Strong correlation is also reported in controls with cirrhosis or HCV infection and studies using PCR-RFLP genotyping. ConclusionsThe study supports that EGF rs4444903 polymorphism is a genetic contributor to liver cirrhosis and HCC in the overall population. Nevertheless, this conclusion must be confirmed by larger studies with more diverse ethnic populations.

show abstract

“…EGF +61 A>G polymorphism was analyzed in the same DNA samples used to access EGFR mutation. Genotyping was performed using quantitative real‐time PCR, with a commercially available TaqMan genotyping assay (ThermoFisher, USA) (C_27031637_10 [ EGF +61 A>G]) in the QuantStudio 6 Flex Real‐Time PCR System (ThermoFisher, USA) and under standard cycling, as previously reported 8 …”

Section: Methodsmentioning

confidence: 99%

“…2 In lung cancer, conflicting results have been reported in different populations. [8][9][10][11] Importantly, in advanced rectal cancer, EGF+61 A>G SNP predicted a complete pathologic response to cetuximab, an anti-EGFR monoclonal antibody. 12 Although cetuximab and TKIs are two different forms of therapies directed at EGFR, they both result in blocking signal transduction.…”

Section: Introductionmentioning

confidence: 99%

“…A single nucleotide polymorphism (SNP) in the 5′ untranslated region of the EGF gene ( EGF +61 A>G — rs4444903) has been associated with increased levels of EGF and consequently is a risk for cancer development of distinct tumors 2 . In lung cancer, conflicting results have been reported in different populations 8–11 . Importantly, in advanced rectal cancer, EGF+61 A>G SNP predicted a complete pathologic response to cetuximab, an anti‐EGFR monoclonal antibody 12 …”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

EGF+61 A>G polymorphism does not predict response to first‐generation EGFR tyrosine kinase inhibitors in lung cancer patients

Leal¹,

Laus

Cavagna

et al. 2020

Thoracic Cancer

Self Cite

View full text Add to dashboard Cite

Epidermal growth factor (EGF) and its receptor (EGFR) play a paramount role in lung carcinogenesis. The polymorphism in the EGF promoter region EGF +61A>G (rs4444903) has been associated with cancer susceptibility, but its role in lung cancer patients treated with tyrosine kinase inhibitors (TKIs) remains unknown. Here, we aimed to evaluate the predictive and prognostic role of EGF +61A>G SNP in lung cancer from Brazilian EGFR-mutated TKI-treated patients. Herein, patients carrying EGFR-sensitizing mutations submitted to TKI treatment (gefitinib/erlotinib) were analyzed (n = 111) for EGF+61A>G genotype by TaqMan genotyping assay. TKI treatment was classified as partial response (PR), stable disease (SD), and disease progression (DP), according to RECIST1.1. Association analysis was assessed by chi-square and Fisher's test (univariate) and multinomial model (multivariate) and survival analysis by Kaplan-Meier method and log-rank test. The EGF+61A>G genotype frequencies observed were: AA = 31.5% (n = 35), AG = 49.6% (n = 55) and GG = 18.9% (n = 21). The allelic frequencies were 56.3% for A, and 43.7% for G and the population was in Hardy-Weinberg equilibrium (P = 0.94). EGF+61A>G codominant model (AA vs. AG vs. GG) was associated with a response to TKIs (P = 0.046), as well as a recessive model (AA vs. AG + GG; P = 0.023). The multinomial regression showed an association between the codominant model (AG) and recessive model (AG + GG) with SD compared with DP (P = 0.01;OR = 0.08; 95% CI = 0.01-0.60 and P = 0.02; OR = 0.12; 95% CI = 0.20-0.72, respectively). No association between genotypes and progression-free or overall survival was observed. In conclusion, the EGF+61 polymorphism (AG and AG + GG) was independently associated with stable disease in lung cancer patients although it was not associated with the overall response rate to first-generation TKIs or patient outcome.

show abstract

EGF+61 A>G polymorphism is not associated with lung cancer risk in the Brazilian population

Cited by 5 publications

References 26 publications

The association of epidermal growth factor variant with oral squamous cell carcinoma

The association of epidermal growth factor variant with oral squamous cell carcinoma

EGF rs4444903 polymorphism is associated with risk of HCV-related cirrhosis and HBV/HCV-related hepatocellular carcinoma

EGF+61 A>G polymorphism does not predict response to first‐generation EGFR tyrosine kinase inhibitors in lung cancer patients

Contact Info

Product

Resources

About